Arvinas and Pfizer Breast Cancer Trial Shows Promising Results

Arvinas Holding Company (ARVN) has issued an announcement.

Arvinas, Inc. and Pfizer have revealed promising results from their Phase 1b trial of vepdegestrant combined with palbociclib (IBRANCE®) in treating ER+/HER2- breast cancer in patients with multiple prior lines of therapy. The latest follow-up data, consistent with earlier findings, showed a high clinical benefit rate and an overall response rate, with a median progression-free survival of over 11 months, which extended to nearly 14 months at the recommended Phase 3 dose. These outcomes, presented at the 2024 ESMO Breast Cancer Annual Congress, coupled with a manageable safety profile, indicate the potential of this treatment regimen in heavily pre-treated breast cancer patients.

See more insights into ARVN stock on TipRanks’ Stock Analysis page.